StockNews.com Downgrades Phibro Animal Health (NASDAQ:PAHC) to Buy

Phibro Animal Health (NASDAQ:PAHC) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.

A number of other equities research analysts have also weighed in on the stock. JPMorgan Chase & Co. assumed coverage on shares of Phibro Animal Health in a report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 price objective on the stock. Bank of America raised their price objective on shares of Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research note on Friday, August 30th. Finally, Barclays lifted their target price on shares of Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research report on Tuesday, November 12th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, Phibro Animal Health currently has an average rating of “Hold” and a consensus price target of $16.50.

Phibro Animal Health Stock Performance

NASDAQ:PAHC opened at $23.75 on Wednesday. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.69 and a current ratio of 3.23. The stock has a market capitalization of $961.88 million, a P/E ratio of 55.23, a PEG ratio of 0.64 and a beta of 0.51. The company has a 50 day moving average price of $22.96 and a 200 day moving average price of $19.84. Phibro Animal Health has a fifty-two week low of $9.49 and a fifty-two week high of $25.98.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, August 28th. The company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. The firm had revenue of $273.16 million during the quarter, compared to analysts’ expectations of $262.44 million. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%. Equities research analysts forecast that Phibro Animal Health will post 1.59 EPS for the current year.

Insider Transactions at Phibro Animal Health

In related news, Director E Thomas Corcoran purchased 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The shares were purchased at an average cost of $20.02 per share, with a total value of $100,100.00. Following the completion of the acquisition, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $500,500. The trade was a 25.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 50.07% of the company’s stock.

Institutional Trading of Phibro Animal Health

A number of institutional investors and hedge funds have recently modified their holdings of PAHC. CWM LLC grew its position in shares of Phibro Animal Health by 89.8% during the second quarter. CWM LLC now owns 2,188 shares of the company’s stock worth $37,000 after acquiring an additional 1,035 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of Phibro Animal Health during the third quarter valued at $70,000. Quantbot Technologies LP acquired a new stake in shares of Phibro Animal Health during the third quarter valued at approximately $70,000. Summit Securities Group LLC acquired a new stake in Phibro Animal Health during the 2nd quarter valued at $83,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in Phibro Animal Health by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock valued at $88,000 after purchasing an additional 1,522 shares during the period. 99.34% of the stock is owned by institutional investors and hedge funds.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.